- Home
- GHRS vs CGBD Comparison
GHRS vs CGBD Comparison
Compare GHRS & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- CGBD
- Stock Information
- Founded
- GHRS 2018
- CGBD 2012
- Country
- GHRS Ireland
- CGBD United States
- Employees
- GHRS N/A
- CGBD N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- CGBD Finance: Consumer Services
- Sector
- GHRS Health Care
- CGBD Finance
- Exchange
- GHRS Nasdaq
- CGBD Nasdaq
- Market Cap
- GHRS 874.0M
- CGBD 1.0B
- IPO Year
- GHRS 2021
- CGBD 2017
- Fundamental
- Price
- GHRS $12.22
- CGBD $13.71
- Analyst Decision
- GHRS Strong Buy
- CGBD Hold
- Analyst Count
- GHRS 8
- CGBD 5
- Target Price
- GHRS $30.63
- CGBD $14.63
- AVG Volume (30 Days)
- GHRS 183.0K
- CGBD 357.4K
- Earning Date
- GHRS 08-07-2025
- CGBD 11-04-2025
- Dividend Yield
- GHRS N/A
- CGBD 12.36%
- EPS Growth
- GHRS N/A
- CGBD N/A
- EPS
- GHRS N/A
- CGBD 1.14
- Revenue
- GHRS N/A
- CGBD $234,464,000.00
- Revenue This Year
- GHRS N/A
- CGBD $14.68
- Revenue Next Year
- GHRS N/A
- CGBD $5.53
- P/E Ratio
- GHRS N/A
- CGBD $12.02
- Revenue Growth
- GHRS N/A
- CGBD N/A
- 52 Week Low
- GHRS $6.00
- CGBD $13.12
- 52 Week High
- GHRS $20.50
- CGBD $18.64
- Technical
- Relative Strength Index (RSI)
- GHRS 37.28
- CGBD 45.80
- Support Level
- GHRS $13.71
- CGBD $13.61
- Resistance Level
- GHRS $14.59
- CGBD $13.91
- Average True Range (ATR)
- GHRS 0.73
- CGBD 0.19
- MACD
- GHRS -0.09
- CGBD -0.01
- Stochastic Oscillator
- GHRS 4.62
- CGBD 23.17
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.